Literature DB >> 16167126

[Cost of fertility and erectile dysfunction therapy: who has to pay what in the GVK?].

I Schroeder-Printzen1, J Schroeder-Printzen, E W Hauck, W Weidner.   

Abstract

From 1 January 2004 new legislation changed the liability of the public health insurance regarding diagnostic and therapy both of erectile dysfunction and infertility. Before 2004 medical therapy of erectile dysfunction (autoinjection therapy, PDE5 inhibitors) was included in the coverage of the general health insurance; however, it is now excluded by law. Before 2004 sterilization was covered by public health insurance only if medically indicated. The costs of vasovasostomy or artificial fertilization after sterilization were only covered by health insurance if the sterilization was carried out for medical reasons. In the field of infertility the liability of statutory health insurance has only been restricted concerning artificial fertilization. Since 2004 there have been restrictions concerning the age of the insured person, and 50% of the costs have to be payed by the patient herself. Moreover, for the different methods of artificial fertilization, the number of trials and the indications have been defined by the Federal Committee. The statutory health insurance is not liable if the number of trials exceeds the limit.

Entities:  

Mesh:

Year:  2005        PMID: 16167126     DOI: 10.1007/s00120-005-0908-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  1 in total

Review 1.  [Diagnosis and therapy of erectile dysfunction: a function of legal health insurance?].

Authors:  I Schroeder-Printzen; J Schroeder-Printzen; W Weidner; R H Ringert
Journal:  Urologe A       Date:  1994-05       Impact factor: 0.639

  1 in total
  1 in total

1.  [New aspects of case law on andrological questions: what does this mean for physicians in private practice?].

Authors:  I Schroeder-Printzen; J Schroeder-Printzen; J Gleissner; W Weidner
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.